z-logo
open-access-imgOpen Access
In situ encapsulation of praziquantel through methyl methacrylate/diethylaminoethyl methacrylate and MMA / DMAEMA miniemulsion copolymerizations in presence of distinct ionic surfactants
Author(s) -
Alves Jéssica Bentes,
Franckini Paiva Thamiris,
Salim Vera Martins,
Conceição Ferraz Helen,
Pinto José Carlos
Publication year - 2021
Publication title -
spe polymers
Language(s) - English
Resource type - Journals
ISSN - 2690-3857
DOI - 10.1002/pls2.10037
Subject(s) - miniemulsion , cationic polymerization , methacrylate , methyl methacrylate , materials science , polymer chemistry , zeta potential , polymer , pulmonary surfactant , chemical engineering , nanoparticle , polymerization , nanotechnology , composite material , engineering
Schistosomiasis is a neglected tropical disease that affects primarily the poorest and most vulnerable populations. Although praziquantel (PZQ) is the drug used most frequently for treatment of schistosomiasis, PZQ presents unpleasant bitter taste and low solubility in water, which prejudice the implementation of pediatric treatments. For this reason, the main purpose of the present work was the production of stable nanoparticles loaded with PZQ through in situ miniemulsion copolymerizations of methyl methacrylate (MMA) with diethylaminoethyl methacrylate (DEAEMA) or dimethylaminoethyl methacrylate (DMAEMA). Due to the cationic nature of the comonomers, the use of different ionic surfactants was also investigated. Nanoparticles with narrow particle size distributions, characteristic average diameters ranging from 50 nm to 110 nm, and loaded with 20 wt% of PZQ were manufactured successfully PZQ encapsulation efficiencies were higher than 97 wt% and PZQ was homogeneously dispersed in the final polymer matrix. Finally, the use of a cationic surfactant with DEAEMA cationic comonomer led to more stable latexes because of the high absolute value of the zeta potential.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here